Agilent (A) PT Raised to $185 at RBC Capital
RBC Capital analyst Dan Leonard raised the price target on Agilent (NYSE: A) to $185.00 (from $155.00) while maintaining an Outperform rating.
The analyst commented: "Broad Beat, Pharma Leads, Product Cycles Firing; Our constructive view on Agilent is anchored by building product cycle momentum across key instrument platforms, exposure to drug manufacturing, and minimal aca/govt drag. The company's FYQ3 beat and guidance increase support our thesis. Agilent exceeded Street expectations, flagging strength in several product areas, early orders related to pharma reshoring, and strength in advanced materials. We've increased our forecasts to reflect the business momentum and price target (to $185 from $155), and maintain our Outperform rating."